Drug Profile
CEN 109
Alternative Names: 18F-EF5; CEN-109Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Pennsylvania; University of Turku
- Class Diagnostic agents; Radiopharmaceutical diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Jun 2015 No recent reports of development identified - Phase-II for Cancer (Diagnosis) in USA (Parenteral)
- 17 Jun 2015 No recent reports of development identified - Phase-I for Cancer (Diagnosis) in Finland (Parenteral)
- 24 May 2011 Phase-II clinical trials in Cancer in USA (Parenteral)